A carregar...
New developments in the management of relapsed/refractory multiple myeloma – the role of ixazomib
Ixazomib is the first oral proteasome inhibitor to be approved, in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy. Approval was on the basis of results from the phase 3, double-blind, placebo-controlle...
Na minha lista:
| Publicado no: | J Blood Med |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5573039/ https://ncbi.nlm.nih.gov/pubmed/28860887 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JBM.S102328 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|